ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. MGNX, a biopharmaceutical firm targeted on creating, manufacturing and commercializing progressive antibody-based therapeutics for the remedy of most cancers, as we speak introduced that the Firm will launch its monetary outcomes for the third quarter of 2024 after the market closes on Tuesday, November 5, 2024. MacroGenics will host a convention name to debate the monetary outcomes and up to date company progress on Tuesday, November 5, 2024, at 4:30 pm ET.
Convention Name Info
To take part through phone, please register upfront through this link. Upon registration, all phone individuals will obtain a affirmation electronic mail detailing how you can be a part of the convention name, together with the dial-in quantity together with a singular passcode and registrant ID that can be utilized to entry the decision. The listen-only webcast of the convention name will be accessed underneath “Occasions & Shows” within the Investor Relations part of the Firm’s web site at http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast can be out there shortly after the conclusion of the decision and archived on the Firm’s web site for 30 days following the decision.
About MacroGenics, Inc.
MacroGenics (the Firm) is a biopharmaceutical firm targeted on creating, manufacturing and commercializing progressive monoclonal antibody-based therapeutics for the remedy of most cancers. The Firm generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based expertise platforms, which have applicability throughout broad therapeutic domains. The mixture of MacroGenics’ expertise platforms and protein engineering experience has allowed the Firm to generate promising product candidates and enter into a number of strategic collaborations with world pharmaceutical and biotechnology firms. For extra data, please see the Firm’s web site at www.macrogenics.com. MacroGenics and the MacroGenics brand are logos or registered logos of MacroGenics, Inc.
###
CONTACTS: Jim Karrels, Senior Vice President, CFO 1-301-251-5172, [email protected]
Market Information and Information dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
